{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:19Z","timestamp":1791559399097,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA229174"],"award-info":[{"award-number":["R01-CA229174"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA249940"],"award-info":[{"award-number":["R01-CA249940"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Deletion of <jats:italic>TRAF2<\/jats:italic> or <jats:italic>TRAF3<\/jats:italic> in B cells prolongs their survival. However, it remains unknown whether deletion of such factors affects B cells\u2019 ability to tolerate DNA damage, which can be induced by chemotherapeutics and cause apoptosis. Genetic alterations of <jats:italic>TRAF2<\/jats:italic> or <jats:italic>TRAF3<\/jats:italic> are observed in subsets of human B-cell lymphomas and B cell-specific deletion of <jats:italic>TRAF3<\/jats:italic> led to lymphoma development in aged mice. However, it remains unknown whether double deficiency of <jats:italic>TRAF2<\/jats:italic> and <jats:italic>TRAF3<\/jats:italic> accelerates B-cell lymphomagenesis. Here, we showed that B cell-specific TRAF2\/3 double deficient (B-TRAF2\/3-DKO) B cells were remarkably more resistant to DNA damage-induced apoptosis via upregulating cIAP2 and XIAP, which in turn attenuates caspase-3 activation. Mechanistically, resistance to DNA damage-induced apoptosis required NF-\u03baB2, which effects by upregulating XIAP and cIAP2 transcription. B-TRAF2\/3-DKO mice exhibited a shorter lifespan and succumbed to splenomegaly and lymphadenopathy. Unexpectedly, the incidence of B-cell lymphoma development in B-TRAF2\/3-DKO mice was relatively rare (\u223c10%). Sequencing B cell receptor repertoire of diseased B cells revealed that TRAF2\/3 deficiency caused abnormal oligoclonal or clonal expansion of B cells. While a fraction of mutant B cells (25\u201343%) from aged diseased mice harbored recurrent chromosomal translocations, primary B cells isolated from young B-TRAF2\/3-DKO mice had no detectable chromosomal alterations, suggesting that TRAF2\/3 deficiency per se does not cause evident genomic instability in B cells. Chemo-resistant TRAF3-deficient B-cell lymphomas were sensitized to chemotherapeutic drugs by blocking IAP activity using IAP antagonist. We conclude that double deficiency of <jats:italic>TRAF2<\/jats:italic> and <jats:italic>TRAF3<\/jats:italic> does not accelerate B-cell lymphomagenesis. Our studies provide insight into mechanisms regulating DNA damage-induced apoptosis and may help develop effective therapies targeting mutant B-cell lymphomas using IAP antagonist.<\/jats:p>","DOI":"10.1038\/s41419-023-06122-2","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T03:26:15Z","timestamp":1694143575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["TRAF2\/3 deficient B cells resist DNA damage-induced apoptosis via NF-\u03baB2\/XIAP\/cIAP2 axis and IAP antagonist sensitizes mutant lymphomas to chemotherapeutic drugs"],"prefix":"10.1038","volume":"14","author":[{"given":"Monika","family":"Vashisht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaibin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessy","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlie A.","family":"McKelvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4343-2527","authenticated-orcid":false,"given":"Jing H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"6122_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14:517\u201334.","journal-title":"Nat Rev Cancer"},{"key":"6122_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5513","volume":"5","author":"DF Fang","year":"2014","unstructured":"Fang DF, He K, Wang N, Sang ZH, Qiu X, Xu G, et al. NEDD4 ubiquitinates TRAF3 to promote CD40-mediated AKT activation. Nat Commun. 2014;5:4513.","journal-title":"Nat Commun"},{"key":"6122_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/imr.12299","volume":"266","author":"WW Lin","year":"2015","unstructured":"Lin WW, Hostager BS, Bishop GA. TRAF3, ubiquitination, and B-lymphocyte regulation. Immunol Rev. 2015;266:46\u201355.","journal-title":"Immunol Rev"},{"key":"6122_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/ni.1676","volume":"9","author":"BJ Zarnegar","year":"2008","unstructured":"Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol. 2008;9:1371\u20138.","journal-title":"Nat Immunol"},{"key":"6122_CR5","doi-asserted-by":"publisher","first-page":"830","DOI":"10.4049\/jimmunol.2000322","volume":"205","author":"Z Chen","year":"2020","unstructured":"Chen Z, Krinsky A, Woolaver RA, Wang X, Chen SMY, Popolizio V, et al. TRAF3 acts as a checkpoint of B cell receptor signaling to control antibody class switch recombination and anergy. J Immunol. 2020;205:830\u201341.","journal-title":"J Immunol"},{"key":"6122_CR6","doi-asserted-by":"publisher","first-page":"100465","DOI":"10.1016\/j.jbc.2021.100465","volume":"296","author":"AL Whillock","year":"2021","unstructured":"Whillock AL, Ybarra TK, Bishop GA. TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells. J Biol Chem. 2021;296:100465.","journal-title":"J Biol Chem"},{"key":"6122_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1074-7613(00)80497-5","volume":"5","author":"Y Xu","year":"1996","unstructured":"Xu Y, Cheng GH, Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity. 1996;5:407\u201315.","journal-title":"Immunity"},{"key":"6122_CR8","doi-asserted-by":"publisher","first-page":"45382","DOI":"10.1074\/jbc.M306708200","volume":"278","author":"BS Hostager","year":"2003","unstructured":"Hostager BS, Haxhinasto SA, Rowland SL, Bishop GA. Tumor necrosis factor receptor-associated factor 2 (TRAF2)-deficient B lymphocytes reveal novel roles for TRAF2 in CD40 signaling. J Biol Chem. 2003;278:45382\u201390.","journal-title":"J Biol Chem"},{"key":"6122_CR9","doi-asserted-by":"publisher","first-page":"26243","DOI":"10.1074\/jbc.M403286200","volume":"279","author":"G Liao","year":"2004","unstructured":"Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem. 2004;279:26243\u201350.","journal-title":"J Biol Chem"},{"key":"6122_CR10","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.4049\/jimmunol.173.9.5546","volume":"173","author":"P Xie","year":"2004","unstructured":"Xie P, Bishop GA. Roles of TNF receptor-associated factor 3 in signaling to B lymphocytes by carboxyl-terminal activating regions 1 and 2 of the EBV-encoded oncoprotein latent membrane protein 1. J Immunol. 2004;173:5546\u201355.","journal-title":"J Immunol"},{"key":"6122_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nature04369","volume":"439","author":"H Hacker","year":"2006","unstructured":"Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature. 2006;439:204\u20137.","journal-title":"Nature"},{"key":"6122_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","volume":"12","author":"JJ Keats","year":"2007","unstructured":"Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12:131\u201344.","journal-title":"Cancer Cell"},{"key":"6122_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","volume":"12","author":"CM Annunziata","year":"2007","unstructured":"Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12:115\u201330.","journal-title":"Cancer Cell"},{"key":"6122_CR14","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.1182\/blood-2009-09-243535","volume":"115","author":"YN Demchenko","year":"2010","unstructured":"Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and\/or alternative NF-kappaB pathway activation in multiple myeloma. Blood. 2010;115:3541\u201352.","journal-title":"Blood"},{"key":"6122_CR15","doi-asserted-by":"publisher","first-page":"209670","DOI":"10.1155\/2014\/209670","volume":"2014","author":"J Smetana","year":"2014","unstructured":"Smetana J, Frohlich J, Zaoralova R, Vallova V, Greslikova H, Kupska R, et al. Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience. Biomed Res Int. 2014;2014:209670.","journal-title":"Biomed Res Int"},{"key":"6122_CR16","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1182\/blood-2011-06-359166","volume":"118","author":"D Rossi","year":"2011","unstructured":"Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C, et al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood. 2011;118:4930\u20134.","journal-title":"Blood"},{"key":"6122_CR17","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-08-3701","volume":"69","author":"E Braggio","year":"2009","unstructured":"Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom\u2019s macroglobulinemia. Cancer Res. 2009;69:3579\u201388.","journal-title":"Cancer Res"},{"key":"6122_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1365-2141.2012.09113.x","volume":"157","author":"C Otto","year":"2012","unstructured":"Otto C, Giefing M, Massow A, Vater I, Gesk S, Schlesner M, et al. Genetic lesions of the TRAF3 and MAP3K14 genes in classical Hodgkin lymphoma. Br J Haematol. 2012;157:702\u20138.","journal-title":"Br J Haematol"},{"key":"6122_CR19","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/leu.2009.149","volume":"23","author":"I Nagel","year":"2009","unstructured":"Nagel I, Bug S, Tonnies H, Ammerpohl O, Richter J, Vater I, et al. Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33). Leukemia. 2009;23:2153\u20135.","journal-title":"Leukemia"},{"key":"6122_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20:87\u201392.","journal-title":"Nat Med"},{"key":"6122_CR21","doi-asserted-by":"publisher","first-page":"eabn3800","DOI":"10.1126\/sciimmunol.abn3800","volume":"7","author":"W Rae","year":"2022","unstructured":"Rae W, Sowerby JM, Verhoeven D, Youssef M, Kotagiri P, Savinykh N, et al. Immunodeficiency, autoimmunity, and increased risk of B cell malignancy in humans with TRAF3 mutations. Sci Immunol. 2022;7:eabn3800.","journal-title":"Sci Immunol"},{"key":"6122_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.immuni.2007.07.012","volume":"27","author":"P Xie","year":"2007","unstructured":"Xie P, Stunz LL, Larison KD, Yang B, Bishop GA. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity. 2007;27:253\u201367.","journal-title":"Immunity"},{"key":"6122_CR23","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2011.309","volume":"26","author":"CR Moore","year":"2012","unstructured":"Moore CR, Liu Y, Shao C, Covey LR, Morse HC 3rd, Xie P. Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice. Leukemia. 2012;26:1122\u20137.","journal-title":"Leukemia"},{"key":"6122_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.immuni.2008.01.009","volume":"28","author":"S Gardam","year":"2008","unstructured":"Gardam S, Sierro F, Basten A, Mackay F, Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity. 2008;28:391\u2013401.","journal-title":"Immunity"},{"key":"6122_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.immuni.2004.09.011","volume":"21","author":"AP Grech","year":"2004","unstructured":"Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity. 2004;21:629\u201342.","journal-title":"Immunity"},{"key":"6122_CR26","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1073\/pnas.0500187102","volume":"102","author":"J Hauer","year":"2005","unstructured":"Hauer J, Puschner S, Ramakrishnan P, Simon U, Bongers M, Federle C, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2\/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA. 2005;102:2874\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6122_CR27","doi-asserted-by":"publisher","first-page":"12971","DOI":"10.1074\/jbc.M109.076091","volume":"285","author":"P Bista","year":"2010","unstructured":"Bista P, Zeng W, Ryan S, Bailly V, Browning JL, Lukashev ME. TRAF3 controls activation of the canonical and alternative NFkappaB by the lymphotoxin beta receptor. J Biol Chem. 2010;285:12971\u20138.","journal-title":"J Biol Chem"},{"key":"6122_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1189\/jlb.2MR0216-063R","volume":"100","author":"GA Bishop","year":"2016","unstructured":"Bishop GA. TRAF3 as a powerful and multitalented regulator of lymphocyte functions. J Leukoc Biol. 2016;100:919\u201326.","journal-title":"J Leukoc Biol"},{"key":"6122_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.4049\/jimmunol.1401548","volume":"194","author":"AI Lalani","year":"2015","unstructured":"Lalani AI, Moore CR, Luo C, Kreider BZ, Liu Y, Morse HC 3rd, et al. Myeloid cell TRAF3 regulates immune responses and inhibits inflammation and tumor development in mice. J Immunol. 2015;194:334\u201348.","journal-title":"J Immunol"},{"key":"6122_CR30","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3324\/haematol.2017.175992","volume":"103","author":"X Wang","year":"2018","unstructured":"Wang X, Chen Z, Mishra AK, Silva A, Ren W, Pan Z, et al. Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition. Haematologica. 2018;103:466\u201376.","journal-title":"Haematologica"},{"key":"6122_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-015-0230-5","volume":"9","author":"Z Chen","year":"2016","unstructured":"Chen Z, Elos MT, Viboolsittiseri SS, Gowan K, Leach SM, Rice M, et al. Combined deletion of Xrcc4 and Trp53 in mouse germinal center B cells leads to novel B cell lymphomas with clonal heterogeneity. J Hematol Oncol. 2016;9:2.","journal-title":"J Hematol Oncol"},{"key":"6122_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11684-012-0215-5","volume":"6","author":"JH Wang","year":"2012","unstructured":"Wang JH. Mechanisms and impacts of chromosomal translocations in cancers. Front Med. 2012;6:263\u201374.","journal-title":"Front Med"},{"key":"6122_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep35349","volume":"6","author":"N Mambetsariev","year":"2016","unstructured":"Mambetsariev N, Lin WW, Wallis AM, Stunz LL, Bishop GA. TRAF3 deficiency promotes metabolic reprogramming in B cells. Sci Rep. 2016;6:35349.","journal-title":"Sci Rep"},{"key":"6122_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49390-9","volume":"9","author":"AL Whillock","year":"2019","unstructured":"Whillock AL, Mambetsariev N, Lin WW, Stunz LL, Bishop GA. TRAF3 regulates the oncogenic proteins Pim2 and c-Myc to restrain survival in normal and malignant B cells. Sci Rep. 2019;9:12884.","journal-title":"Sci Rep"},{"key":"6122_CR35","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1084\/jem.20082271","volume":"205","author":"JH Wang","year":"2008","unstructured":"Wang JH, Alt FW, Gostissa M, Datta A, Murphy M, Alimzhanov MB, et al. Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. J Exp Med. 2008;205:3079\u201390.","journal-title":"J Exp Med"},{"key":"6122_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3389\/fonc.2014.00197","volume":"4","author":"P Obexer","year":"2014","unstructured":"Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol. 2014;4:197.","journal-title":"Front Oncol"},{"key":"6122_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13578-020-00521-0","volume":"11","author":"R Frazzi","year":"2021","unstructured":"Frazzi R. BIRC3 and BIRC5: multi-faceted inhibitors in cancer. Cell Biosci. 2021;11:8.","journal-title":"Cell Biosci"},{"key":"6122_CR38","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3390\/cancers14071671","volume":"14","author":"P Cetraro","year":"2022","unstructured":"Cetraro P, Plaza-Diaz J, MacKenzie A, Abadia-Molina F. A review of the current impact of inhibitors of apoptosis proteins and their repression in cancer. Cancers (Basel). 2022;14:1671.","journal-title":"Cancers (Basel)"},{"key":"6122_CR39","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1038\/ncb1789","volume":"10","author":"M Gyrd-Hansen","year":"2008","unstructured":"Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W, et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. Nat Cell Biol. 2008;10:1309\u201317.","journal-title":"Nat Cell Biol"},{"key":"6122_CR40","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.molcel.2007.05.006","volume":"26","author":"M Lu","year":"2007","unstructured":"Lu M, Lin SC, Huang Y, Kang YJ, Rich R, Lo YC, et al. XIAP induces NF-kappaB activation via the BIR1\/TAB1 interaction and BIR1 dimerization. Mol Cell. 2007;26:689\u2013702.","journal-title":"Mol Cell"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06122-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06122-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06122-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T03:26:38Z","timestamp":1694143598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-023-06122-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["6122"],"URL":"https:\/\/doi.org\/10.1038\/s41419-023-06122-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"13 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal work was approved by the Institutional Animal Care and Use Committee of University of Colorado Anschutz Medical Campus (Aurora, CO) and University of Pittsburgh (Pittsburgh, PA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"599"}}